Novartis’ Pluvicto Wins FDA Approval for Earlier Prostate Cancer Treatment
SILVER SPRING, Md., July 31, 2026 The U.S. Food and Drug Administration (FDA) has approved Novartis’ Pluvicto (lutetium Lu...
Pluvicto
Advertisement
Convergent’s CONV01-α Shows Promising Activity in Post-Lu-PSMA Prostate Cancer Phase 2 Study
CAMBRIDGE, Mass., June 2, 2026 Convergent Therapeutics announced positive interim Phase 2 data from its CONVERGE-01 study evaluating CONV01-α...
Novartis Highlights New Cancer Data at ASCO & EHA 2026
BASEL, Switzerland, May 21, 2026 Novartis announced it will present more than 65 company-sponsored and investigator-sponsored abstracts at the...
Novartis to Present Key Prostate and Breast Cancer Data at ESMO
BASEL, Switzerland, Sept. 26, 2025 — Novartis announced it will present 34 abstracts from its oncology pipeline at the...
Advertisement
